Revenue |
6 Months Ended |
|---|---|
Jun. 30, 2019 | |
| Revenue from Contract with Customer [Abstract] | |
| Revenue |
Revenue
Revenue from the Company’s Discovery Services comes from preclinical oncology and immuno-oncology services offered to our biotechnology and pharmaceutical customers. The Company is a leader in orthotopic and metastases tumor models and offers whole body imaging, in addition to toxicology testing and bionalytical analysis. Our Discovery Services are designed to support new compounds being studied to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug (IND) filing.
During the six months ended June 30, 2019, three customers accounted for approximately 68% of our consolidated revenue from continuing operations. During the six months ended June 30, 2018, two customers accounted for approximately 37% of our consolidated revenue from continuing operations.
During the three months ended June 30, 2019, one customer accounted for approximately 65% of our consolidated revenue from continuing operations. During the three months ended June 30, 2018, four customers accounted for approximately 69% of our consolidated revenue from continuing operations.
Remaining Performance Obligations:
Services offered under Discovery Services frequently take time to complete under their respective contacts. These times vary depending on specific contract arrangements including the length of the study and how samples are delivered to us for processing. In the case of Discovery Services, the duration of performance obligations is less than one year.
|